


VISCHER ADVISES AMR ACTION FUND ON ITS INVESTMENT IN BIOVERSYS

Posted on 26 January 2023



Category: [Corporate](#)

Tags: [AMR Action Fund](#), [Balthasar Mueller](#), [Matthias Staehelin](#), [Natacha Tang](#), [Sebastian Flückiger](#), [Slider](#), [Vischer](#)



As we have informed [here](#), the **AMR Action Fund**, the world's largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in **BioVersys**, a clinical-stage company based in Basel, Switzerland.

The transaction marks the Fund's first investment in Europe and is an important step toward building an international portfolio of companies that are de-veloping urgently needed antimicrobials. BioVersys is focusing on research and develop-ment of therapies for life-threatening multidrug-resistant bacterial infections and targeted mi-crobiome modulation. With this investment, BioVersys extended its Series C investment round to CHF 32.6m.

VISCHER has advised AMR Action Fund with a team lead by partner **Matthias Staehelin** (pictured) with **Sebastian Flückiger**, **Balthasar Müller** and **Natacha Tang** (all corporate/m&a).